Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Radiotherapy as Adjuvant Treatment for HER2+ UTUC
NCT07498907Phase 3Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in upper tract urothelial carcinoma (UTUC), sponsored by Peking University First Hospital. Started May 2026; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07498907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498907.